Team:Westminster
From 2012.igem.org
(Difference between revisions)
(7 intermediate revisions not shown) | |||
Line 153: | Line 153: | ||
} | } | ||
#bodyContent { | #bodyContent { | ||
+ | } | ||
+ | #three-column | ||
+ | { | ||
+ | margin:0 auto; | ||
+ | width:850px; | ||
+ | margin-top:50px; | ||
+ | |||
} | } | ||
.col | .col | ||
{ | { | ||
- | + | text-align:justify; float:left; margin:5px; | |
} | } | ||
.col h1 | .col h1 | ||
Line 196: | Line 203: | ||
background: url('https://static.igem.org/mediawiki/2012/d/d0/Close-btn.png') #000 no-repeat 2px 2px; | background: url('https://static.igem.org/mediawiki/2012/d/d0/Close-btn.png') #000 no-repeat 2px 2px; | ||
} | } | ||
+ | .right-menu li a, .left-menu li a {background: none} | ||
</style> | </style> | ||
Line 254: | Line 262: | ||
$bar.css("left", "0px"); | $bar.css("left", "0px"); | ||
$bar.css("background", "none"); | $bar.css("background", "none"); | ||
- | $bar.css("background", " | + | $bar.css("background", "rgba(0,0,0,.5)"); |
$bar.css("height", "20px"); | $bar.css("height", "20px"); | ||
$bar.css("border", "none"); | $bar.css("border", "none"); | ||
Line 269: | Line 277: | ||
} | } | ||
</script> | </script> | ||
- | |||
</head> | </head> | ||
<body> | <body> | ||
- | |||
<div id="wrapper"> | <div id="wrapper"> | ||
<div id="header"> | <div id="header"> | ||
- | + | <div id="control-btn" class="btn-cog"></div> | |
<div id="navigation"> | <div id="navigation"> | ||
Line 283: | Line 289: | ||
<li><a href="https://2012.igem.org/Team:Westminster" class="navlink active">Home</a></li> | <li><a href="https://2012.igem.org/Team:Westminster" class="navlink active">Home</a></li> | ||
<li><a href="https://2012.igem.org/Team:Westminster/Team" class="navlink">Team</a></li> | <li><a href="https://2012.igem.org/Team:Westminster/Team" class="navlink">Team</a></li> | ||
- | |||
<li class="submenu-holder"> | <li class="submenu-holder"> | ||
- | <a href="https://2012.igem.org/Team:Westminster | + | <a href="https://2012.igem.org/Team:Westminster/Overview"class="navlink">Project</a> |
<ul class="submenu"> | <ul class="submenu"> | ||
Line 296: | Line 301: | ||
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Safety"class="navlink">Safety</a></li> | <li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Safety"class="navlink">Safety</a></li> | ||
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Journal"class="navlink">Journal</a></li> | <li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Journal"class="navlink">Journal</a></li> | ||
+ | |||
+ | |||
</ul> | </ul> | ||
</li> | </li> | ||
<li><a href="https://2012.igem.org/Team:Westminster/Parts"class="navlink">Parts</a></li> | <li><a href="https://2012.igem.org/Team:Westminster/Parts"class="navlink">Parts</a></li> | ||
<li><a href="https://2012.igem.org/Team:Westminster/Modeling"class="navlink">Modeling</a></li> | <li><a href="https://2012.igem.org/Team:Westminster/Modeling"class="navlink">Modeling</a></li> | ||
- | <li><a href="https://2012.igem.org/Team:Westminster/ | + | <li><a href="https://2012.igem.org/Team:Westminster/Outreach"class="navlink">Outreach</a></li> |
+ | <li><a href="https://2012.igem.org/Team:Westminster/Judging"class="navlink">Judging Criteria</a></li> | ||
- | + | ||
<li><a href="https://2012.igem.org/Team:Westminster/Attributions"class="navlink">Attributions</a></li> | <li><a href="https://2012.igem.org/Team:Westminster/Attributions"class="navlink">Attributions</a></li> | ||
</ul><!-- #navigation-list --> | </ul><!-- #navigation-list --> | ||
</div><!-- #navigation --> | </div><!-- #navigation --> | ||
<div id="logo"> | <div id="logo"> | ||
- | <a href="http://www.igem.org"><img src="https://static.igem.org/mediawiki/igem.org/d/dc/Igem-small-white.png" /></a> | + | <a href="http://www.igem.org" title="iGEM homepage"><img src="https://static.igem.org/mediawiki/igem.org/d/dc/Igem-small-white.png" alt="iGEM logo" width="55" height="44" /></a> |
<a href="https://2012.igem.org/Team:Westminster"> | <a href="https://2012.igem.org/Team:Westminster"> | ||
<img src="https://static.igem.org/mediawiki/2012/a/ae/Logo-white.png" alt="iSTEM - intelligent synthetic tumour eliminating machine" width="172" height="66" title="iSTEM - intelligent synthetic tumour eliminating machine" /> | <img src="https://static.igem.org/mediawiki/2012/a/ae/Logo-white.png" alt="iSTEM - intelligent synthetic tumour eliminating machine" width="172" height="66" title="iSTEM - intelligent synthetic tumour eliminating machine" /> | ||
Line 320: | Line 328: | ||
<h1 style="text-align:left;border:none; color:#fff; position:relative;bottom:0px; left:0px; margin:0px; padding:0px 0px 20px 0px;">Fighting cancer from the inside out</h1> | <h1 style="text-align:left;border:none; color:#fff; position:relative;bottom:0px; left:0px; margin:0px; padding:0px 0px 20px 0px;">Fighting cancer from the inside out</h1> | ||
<div style="color:white; text-align:justify;">Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.<br/><br/> | <div style="color:white; text-align:justify;">Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.<br/><br/> | ||
- | The Westminster iGEM 2012 team aims to combat cancer recurrence by using one key feature of CSCs – increased Aldehyde Dehydrogenase (ALDH) activity. We have used the promoters of 4 different ALDH isoforms present in aggressive forms of cancer to design 3 constucts that will allow us to identify, isolate and eliminate CSC, offering a novel tool for the study of | + | The Westminster iGEM 2012 team aims to combat cancer recurrence by using one key feature of CSCs – increased Aldehyde Dehydrogenase (ALDH) activity. We have used the promoters of 4 different ALDH isoforms present in aggressive forms of cancer to design 3 constucts that will allow us to identify, isolate and eliminate CSC, offering a novel tool for the study of these cells and a potential new anti-cancer therapy for the future.</div> |
Line 330: | Line 338: | ||
</div><!-- #home-main-image --> | </div><!-- #home-main-image --> | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
<div id="three-column"> | <div id="three-column"> | ||
- | <div class="col | + | |
- | < | + | <div class="col"> |
- | + | <img src="https://static.igem.org/mediawiki/igem.org/d/d7/IntegratedDNALogo.jpg" width="146" height="61"/> | |
</div> | </div> | ||
- | <div class="col | + | <div class="col"> |
- | < | + | <img src="https://static.igem.org/mediawiki/igem.org/b/b9/GeneiousLogo.jpg" width="136" height="54"/> |
- | + | ||
</div> | </div> | ||
- | <div class="col | + | <div class="col"> |
- | < | + | <img src="https://static.igem.org/mediawiki/igem.org/a/af/MathWorksLogo.jpg" width="202" height="40"/> |
- | + | </div> | |
+ | <div class="col"> | ||
+ | <img src="https://static.igem.org/mediawiki/igem.org/8/8e/AutodeskLogo.jpg" width="161" height="41"/> | ||
+ | </div> | ||
+ | <div class="col"> | ||
+ | <img src="https://static.igem.org/mediawiki/igem.org/c/c7/UniversityWestminsterLogo.jpg"/> | ||
</div> | </div> | ||
Line 362: | Line 368: | ||
</html> | </html> | ||
+ | |||
+ | [[iGEM 2013]] |
Latest revision as of 18:58, 9 August 2013
Fighting cancer from the inside out
Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.
The Westminster iGEM 2012 team aims to combat cancer recurrence by using one key feature of CSCs – increased Aldehyde Dehydrogenase (ALDH) activity. We have used the promoters of 4 different ALDH isoforms present in aggressive forms of cancer to design 3 constucts that will allow us to identify, isolate and eliminate CSC, offering a novel tool for the study of these cells and a potential new anti-cancer therapy for the future.
The Westminster iGEM 2012 team aims to combat cancer recurrence by using one key feature of CSCs – increased Aldehyde Dehydrogenase (ALDH) activity. We have used the promoters of 4 different ALDH isoforms present in aggressive forms of cancer to design 3 constucts that will allow us to identify, isolate and eliminate CSC, offering a novel tool for the study of these cells and a potential new anti-cancer therapy for the future.